SELLNER, L., M. BRUGGEMANN, M. SCHLITT, H. KNECHT, D. HERRMANN, Tomáš REIGL, Adam KREJČÍ, Vojtěch BYSTRÝ, Nikos DARZENTAS, M. RIEGER, S. DIETRICH, T. LUFT, A.D. HO, M. KNEBA a P. DREGER. GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. Bone Marrow Transplantation. London: Nature Publishing Group, 2017, roč. 52, č. 4, s. 544-551. ISSN 0268-3369. Dostupné z: https://dx.doi.org/10.1038/bmt.2016.305. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1411376, author = {Sellner, L. and Bruggemann, M. and Schlitt, M. and Knecht, H. and Herrmann, D. and Reigl, Tomáš and Krejčí, Adam and Bystrý, Vojtěch and Darzentas, Nikos and Rieger, M. and Dietrich, S. and Luft, T. and Ho, A.D. and Kneba, M. and Dreger, P.}, article_location = {London}, article_number = {4}, doi = {http://dx.doi.org/10.1038/bmt.2016.305}, keywords = {STEM-CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; MARROW TRANSPLANTATION; CLINICAL-SIGNIFICANCE; GENE REARRANGEMENTS; ADULT PATIENTS; STANDARD-RISK; CLL3X TRIAL}, language = {eng}, issn = {0268-3369}, journal = {Bone Marrow Transplantation}, title = {GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses}, url = {https://www.nature.com/articles/bmt2016305}, volume = {52}, year = {2017} }
TY - JOUR ID - 1411376 AU - Sellner, L. - Bruggemann, M. - Schlitt, M. - Knecht, H. - Herrmann, D. - Reigl, Tomáš - Krejčí, Adam - Bystrý, Vojtěch - Darzentas, Nikos - Rieger, M. - Dietrich, S. - Luft, T. - Ho, A.D. - Kneba, M. - Dreger, P. PY - 2017 TI - GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses JF - Bone Marrow Transplantation VL - 52 IS - 4 SP - 544-551 EP - 544-551 PB - Nature Publishing Group SN - 02683369 KW - STEM-CELL TRANSPLANTATION KW - MINIMAL RESIDUAL DISEASE KW - ACUTE LYMPHOBLASTIC-LEUKEMIA KW - CHRONIC LYMPHOCYTIC-LEUKEMIA KW - MARROW TRANSPLANTATION KW - CLINICAL-SIGNIFICANCE KW - GENE REARRANGEMENTS KW - ADULT PATIENTS KW - STANDARD-RISK KW - CLL3X TRIAL UR - https://www.nature.com/articles/bmt2016305 L2 - https://www.nature.com/articles/bmt2016305 N2 - Allogeneic stem cell transplantation (alloSCT) is used for treating patients with T-prolymphocytic leukemia (T-PLL). However, direct evidence of GvL activity in T-PLL is lacking. We correlated minimal residual disease (MRD) kinetics with immune interventions and T-cell receptor (TCR) repertoire diversity alterations in patients after alloSCT for T-PLL. Longitudinal quantitative MRD monitoring was performed by clone-specific real-time PCR of TCR rearrangements (n = 7), and TCR repertoire diversity assessment by nextgeneration sequencing (NGS; n = 3) Although post-transplant immunomodulation (immunosuppression tapering or donor lymphocyte infusions) resulted in significant reduction (>1 log) of MRD levels in 7 of 10 occasions, durable MRD clearance was observed in only two patients. In all three patients analyzed by TCR-NGS, MRD responses were reproducibly associated with a shift from a clonal, T-PLL-driven profile to a polyclonal signature. Novel clonotypes that could explain a clonal GvL effect did not emerge. In conclusion, TCR-based MRD quantification appears to be a suitable tool for monitoring and guiding treatment interventions in T-PLL. The MRD responses to immune modulation observed here provide first molecular evidence for GvL activity in T-PLL which, however, may be often only transient and reliant on a poly-/oligoclonal rather than a monoclonal T-cell response. ER -
SELLNER, L., M. BRUGGEMANN, M. SCHLITT, H. KNECHT, D. HERRMANN, Tomáš REIGL, Adam KREJČÍ, Vojtěch BYSTRÝ, Nikos DARZENTAS, M. RIEGER, S. DIETRICH, T. LUFT, A.D. HO, M. KNEBA a P. DREGER. GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. \textit{Bone Marrow Transplantation}. London: Nature Publishing Group, 2017, roč.~52, č.~4, s.~544-551. ISSN~0268-3369. Dostupné z: https://dx.doi.org/10.1038/bmt.2016.305.
|